Citigroup Inc Global Blood Therapeutics, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$32.4 - $68.18 $45.3 Million - $95.3 Million	1,397,250 Added 738.96%	1,586,334 $108 Million
Q2 2022 Aug 10, 2022	BUY	$22.3 - $37.39 $3.2 Million - $5.36 Million	143,381 Added 313.72%	189,084 $6.04 Million
Q1 2022 May 12, 2022	SELL	$25.68 - $35.59 $3.12 Million - $4.32 Million	-121,425 Reduced 72.65%	45,703 $1.58 Million
Q4 2021 Feb 10, 2022	BUY	$24.9 - $40.26 $1.9 Million - $3.07 Million	76,303 Added 84.01%	167,128 $4.89 Million
Q3 2021 Nov 10, 2021	BUY	$25.48 - $37.34 $2.31 Million - $3.39 Million	90,825 New	90,825 $2.31 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.